Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20250911 | 0.90 | RXFP1 (0.62) | MEN1KMT2APOLBRXFP1ALDH1A1 | |
| SCHEMBL8696232 | 0.81 | POLB (0.55) | MEN1KMT2APOLBRXFP1ALDH1A1 | |
| SCHEMBL8805799 | 0.81 | YES1 (0.74) | MEN1KMT2APOLBRXFP1ALDH1A1 | |
| SCHEMBL5329307 | 0.81 | POLB (0.72) | POLBALDH1A1LMNAPADI4CYP19A1 | |
| SCHEMBL1233547 | 0.80 | ALDH1A1 (0.67) | MEN1KMT2APOLBRXFP1ALDH1A1 | |
| SCHEMBL16977268 | 0.79 | CYP19A1 (0.61) | MEN1KMT2APOLBRXFP1ALDH1A1 | |
| SCHEMBL20248189 | 0.78 | HTR6 (0.62) | POLBTP53MAPT | |
| SCHEMBL24479703 | 0.76 | LMNA (0.77) | MEN1KMT2APOLBRXFP1TP53 | |
| SCHEMBL9054761 | 0.76 | YES1 (0.83) | MEN1KMT2APOLBRXFP1ALDH1A1 | |
| SCHEMBL1859925 | 0.76 | POLB (0.64) | MEN1KMT2APOLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161313-A1 | Inhibitors of Mcl-1 as Drugs to Overcome Resistance to BRAF Inhibitors and MEK Inhibitors | TEXAS TECH UNIVERSITY SYSTEM | 2018-06-14 | — | — | US | disclosed |
| US-20180161313-A1 | Inhibitors of Mcl-1 as Drugs to Overcome Resistance to BRAF Inhibitors and MEK Inhibitors | TEXAS TECH UNIVERSITY SYSTEM | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161313-A1 | Inhibitors of Mcl-1 as Drugs to Overcome Resistance to BRAF Inhibitors and MEK Inhibitors | MCL1, BRAF, RAF1 | MEN1 778/4885KMT2A 1550/4885POLB 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.